CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. Prevention of skin cancer and reduction of keratotic skin lesions during ...
We identified 910 patients with plasma cell disorders from our prospectively maintained database, who had a first attempt at G-CSF-based PBSC mobilization, including MM (565; 62%) or AL (345; 38%), ...
October 24, 2011 — In nonstraightforward bone marrow analysis, the presence of 30% or more CD34+ megakaryocytes is a strong indicator of megaloblastic anemia or a myeloid neoplasm, according to a ...
Immunofluorescence detection of the complement split product C4d along peritubular capillaries in renal allograft biopsies is the mainstay for the diagnosis of antibody-mediated rejection. The extent ...
Epoch-Making Breakthrough of the Stem-Cell Nutritional Supplementation CD34 Nu-Signals®, Currently Undergoing Rigorous Clinical Trials Conducted by Prestigious Medical Institutions to Validate Its ...
Expanding on the Cooperative Center of Excellence in Hematology (CCEH) at Fred Hutchinson Cancer Center’s expertise in providing Human CD34+ HSPCs, we have established a high-efficiency and ...
We've had the opportunity to evaluate the CD34+ cell in the past 20 years, and finally we have a tool that represents a potential breakthrough for patients with CMD, said Douglas Losordo, MD, FACC, ...
Unknown primary tumors metastatic to liver. The majority of patients (97%) mobilized CD34+33- cells, which were usually collected in the greatest quantity on the first day of apheresis. Patients who ...
CAMBRIDGE, Mass. & HAIFA, Israel--(BUSINESS WIRE)--Minovia Therapeutics, a clinical-stage company focused on the development of cell-based Mitochondrial Augmentation Technology (MAT) to treat ...
Polycythemia vera is the ultimate phenotypic consequence of the V617F mutation in Janus kinase 2 (encoded by JAK2), but the extent to which this mutation influences the behavior of the involved CD34+ ...
Mulhouse, France, April 23, 2024 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases will share, for the first-time, promising results from EXCELLENT Phase I/IIb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results